Serum neurofilament light as a biomarker in progressive multiple sclerosis

There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes revealed in early phase trials. In January 2019, the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurology
Autors principals: Kapoor, Raju, Smith, Kathryn E., Allegretta, Mark, Arnold, Douglas L., Carroll, William, Comabella, Manuel, Furlan, Roberto, Harp, Christopher, Kuhle, Jens, Leppert, David, Plavina, Tatiana, Sellebjerg, Finn, Sincock, Caroline, Teunissen, Charlotte E., Topalli, Ilir, von Raison, Florian, Walker, Elizabeth, Fox, Robert J.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2020
Matèries:
Views & Reviews
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7538221/
https://ncbi.nlm.nih.gov/pubmed/32675076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000010346
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars